Stockscreener 앱 받기
12.48
1.89%
-0.24
시간 외 거래:
12.70
0.22
+1.76%
전일 마감가:
$12.72
열려 있는:
$12.68
하루 거래량:
2.85M
Relative Volume:
1.21
시가총액:
$1.07B
수익:
$139.71M
순이익/손실:
$-209.36M
주가수익비율:
-4.2162
EPS:
-2.96
순현금흐름:
$-160.60M
1주 성능:
+25.05%
1개월 성능:
+42.63%
6개월 성능:
-19.59%
1년 성능:
-37.57%
1일 변동 폭
$12.23
$12.95
1주일 범위
$9.68
$13.25
52주 변동 폭
$8.58
$22.50
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
명칭
Syndax Pharmaceuticals Inc
전화
781-419-1400
주소
730 THIRD AVENUE, NEW YORK, MA
SNDX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
12.48 | 1.11B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-05 | 재확인 | BTIG Research | Buy |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-06-28 | 개시 | Jefferies | Buy |
| 2024-01-31 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | 개시 | Mizuho | Buy |
| 2023-10-25 | 개시 | BofA Securities | Buy |
| 2023-10-11 | 개시 | Goldman | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-07-11 | 개시 | Guggenheim | Buy |
| 2023-04-17 | 재개 | BTIG Research | Buy |
| 2023-01-31 | 개시 | Stifel | Buy |
| 2023-01-03 | 개시 | JP Morgan | Overweight |
| 2022-07-28 | 재개 | B. Riley Securities | Buy |
| 2022-04-11 | 개시 | H.C. Wainwright | Buy |
| 2022-02-15 | 개시 | Goldman | Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-05-25 | 개시 | Citigroup | Buy |
| 2021-02-18 | 개시 | B. Riley Securities | Buy |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-05-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-05-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-05-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-13 | 재확인 | H.C. Wainwright | Buy |
| 2019-03-08 | 재확인 | H.C. Wainwright | Buy |
| 2019-01-04 | 개시 | Robert W. Baird | Outperform |
| 2018-01-05 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | 개시 | FBR & Co. | Outperform |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2016-10-07 | 개시 | Guggenheim | Buy |
| 2016-03-28 | 개시 | Citigroup | Buy |
| 2016-03-28 | 개시 | JMP Securities | Mkt Outperform |
| 2016-03-28 | 개시 | Morgan Stanley | Overweight |
모두보기
Syndax Pharmaceuticals Inc 주식(SNDX)의 최신 뉴스
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Rating Upgraded by B. Riley - MarketBeat
Analysts Just Made A Massive Upgrade To Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Forecasts - 富途牛牛
Analysts Just Made A Dazzling Upgrade To Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Forecasts - Yahoo Finance
11 Best Short-Term Stocks to Invest in - Insider Monkey
Syndax jumps after Q2 beat; Citi issues upside catalyst watch - MSN
Syndax Pharmaceuticals Publishes Positive Revumenib Data from BEAT AML Trial - MSN
Q3 Earnings Forecast for SNDX Issued By B. Riley - MarketBeat
Citi Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $51 - 富途牛牛
Syndax targets expanded $10B market opportunity with Revuforj and Niktimvo amid accelerating adoption and guidance for stable expenses - MSN
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Syndax Pharmaceuticals Announces Inducement Stock Grants Under NASDAQ Listing Rule 5635(c)(4) - AInvest
Citigroup Forecasts Strong Price Appreciation for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock - MarketBeat
Citi Raises Syndax Target to $51, Adds Positive Catalyst Watch - AInvest
Citi ups Syndax target, opens ‘upside catalyst watch’ - Yahoo Finance
BTIG Research Raises Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target to $56.00 - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Up After Earnings Beat - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q2 2025 Earnings Call Transcript - Insider Monkey
Three Stocks to Buy Now: Harmony Biosciences, Syndax Pharmaceuticals, and Viper Energy - AInvest
Optimistic Investors Push Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Up 40% But Growth Is Lacking - simplywall.st
Syndax Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Syndax Pharmaceuticals Faces Ongoing and Emerging Business Risks: A Closer Look at SEC Filings - TipRanks
Decoding Syndax Pharmaceuticals Inc (SNDX): A Strategic SWOT Ins - GuruFocus
Citigroup Raises SNDX Price Target Amid "Buy" Rating - AInvest
Syndax Pharmaceuticals’ Earnings Call Highlights Robust Growth - TipRanks
Syndax Pharmaceuticals (NASDAQ:SNDX) Posts Earnings Results, Beats Estimates By $0.18 EPS - MarketBeat
Evaluating the High-Growth Potential of Biopharma Innovators in 2025: A Deep Dive into Day One, Beam Therapeutics, and Syndax Pharmaceuticals - AInvest
Citigroup Raises Syndax PT to $51 from $46, Maintains Buy Rating - AInvest
Syndax Pharmaceuticals (SNDX) Surges on Strong Q2 2025 Results - GuruFocus
BTIG Raises Price Target for SNDX, Maintains Buy Rating | SNDX S - GuruFocus
Syndax Pharmaceuticals Q2 Earnings Exceed Expectations, Citi Issues Upside Catalyst Watch - AInvest
Syndax stock up as Citi issues catalyst watch (SNDX:NASDAQ) - Seeking Alpha
Syndax Stock (SNDX) Moves Higher: Analysts Raise PTs on Strong Revenue, Approaching Catalyst - AskTraders.com
Syndax Pharmaceuticals: The Story Brightens (NASDAQ:SNDX) - Seeking Alpha
Syndax stock price target raised to $20 from $18 at Goldman Sachs - Investing.com Canada
Health Check: How Prudently Does Syndax Pharmaceuticals (NASDAQ:SNDX) Use Debt? - simplywall.st
Syndax Pharmaceuticals Shares Soar 12.62% on Strong Q2 Earnings - AInvest
Syndax: Q2 Earnings Snapshot - New Haven Register
Syndax Pharmaceuticals Reports Strong Q2 2025 Growth - TipRanks
Syndax Pharmaceuticals' Q2 2025: Unpacking Key Contradictions in Revuforj's Impact on Patient Care and Market Growth - AInvest
Syndax Pharmaceuticals Wins Over Wall Street With Strong Drug Gains - Finimize
Syndax Reports Losses, But Wall Street Still Sees Big Upside - Finimize
Syndax Pharmaceuticals: Navigating the Path to Profitability with Two Blockbuster Candidates - AInvest
Syndax Pharmaceuticals, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:SNDX) - Seeking Alpha
Syndax Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Syndax Pharmaceuticals Q2 2025 beats forecasts, stock rises - Investing.com Canada
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Syndax Pharmaceuticals earnings beat by $0.18, revenue topped estimates - Investing.com UK
Syndax Q2 2025 presentation: Strong revenue growth despite widening losses - Investing.com Canada
SNDX Surpasses Revenue Expectations with Strong Product Sales - GuruFocus
Syndax Pharmaceuticals Inc SEC 10-Q Report - TradingView
Syndax Reports 43% Revuforj Growth, $28.6mln Net Revenue in Q2. - AInvest
Syndax Pharmaceuticals Inc (SNDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):